Torsdag 19 November | 22:02:29 Europe / Stockholm

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Filter arrow-icon
Språk arrow-icon
2026-10-30 01:00:00
Progress on strategic priorities and core business performance
CEO Katarina Gabrielson comments on Oriola’s Q3 2026 results
2026-09-29 02:00:00
Why medical translation requires more than linguistic accuracy
Medical information must be accurate, but accuracy alone is not enough. Patients and healthcare professionals also need information that is clear, consistent and appropriate for the context in which it is used
2026-09-02 02:00:00
Regulatory affairs: Is the Nordic self-care market entering a new era?
Legislative changes in Sweden and Finland are set to reshape how patients access certain medicines
2026-08-24 02:00:00
Special licensed medicines help safeguard continuity of care when standard options are unavailable
When a medicine becomes unavailable, the impact extends far beyond supply chain reports and shortage statistics. Special licensed medicines can play an important role in helping patients continue their treatment safely
2026-08-10 02:00:00
From portfolio to growth: how Oriola helps health brands reach more customers
Through a broad wholesale service offering, deep Nordic market knowledge and close customer partnerships, Oriola also helps health brands grow and supports resellers in building relevant assortments for today’s health and wellbeing consumers
2026-08-04 02:00:00
7 trends shaping Nordic pharmaceutical distribution in 2026 and beyond
By: Stig Tornell, Executive Vice President Sales, Oriola Nordic pharmaceutical distribution connects manufacturers with pharmacies, hospitals, healthcare providers, veterinarians and other customer groups. When medicines and health products move safely and efficiently through the supply chain, healthcare systems are better equipped to serve patients and society. For pharmaceutical companies enteri...
2026-07-20 02:00:00
Continued net sales growth in Product segment, Group profitability at last year's level
CEO Katarina Gabrielson comments on Oriola’s Q2 2026 results
2026-06-03 02:00:00
Making Nordic Medical Information simpler – meet our Danish team
Managing Medical Information across the Nordics shouldn’t be complex. At Oriola, we take a different approach: combining strong local expertise with one unified Nordic setup
2026-05-06 02:00:00
Oriola delivers fast, predictable and high quality onboarding of Medical Information
At Oriola, we know that onboarding sets the foundation for the entire collaboration. That is why our Medical Information onboarding model is designed to combine speed with structure, ensuring a predictable go-live and stable operations from day one, supporting both Nordic and EU launches
2026-04-30 02:00:00
First quarter performance in line with expectations
CEO Katarina Gabrielson comments on Oriola’s Q1 2026 results
2026-04-13 02:00:00
Automated dose dispensing of medicines strengthens Finnish healthcare through improved safety, efficiency and better use of resources
Did you know that automated dose dispensing can save an average of 15 hours of nursing time per patient per year?
2026-03-31 02:00:00
Transforming supply chain planning for the future
To improve efficiency and ensure high product availability, Oriola is implementing RELEX, an AI-driven planning tool that will modernise supply chain planning across markets
2026-03-13 01:00:00
Expanding wholesale opportunities with Conaxess Trade
Oriola and Conaxess Trade's partnership, started in 2025, is a good example of initiatives supporting our strategic goal Portfolio and market expansion
2026-03-05 01:00:00
Sustainability remains a key priority
"We are committed to reach net zero emissions across the value chain by 2050"
2026-02-26 01:00:00
Steady progress in adjusted EBITDA and strategic priorities
CEO Katarina Gabrielson comments on Oriola’s full-year 2025 results: We delivered steady progress in line with our expectations, and the second half of the year was particularly strong
2026-01-19 01:00:00
Ensuring reliable vaccine distribution together during the flu season
Vaccine distribution places higher demands on logistics than many other types of pharmaceuticals. For manufacturers, predictable and compliant distribution is essential. For distributors, planning and execution must run without interruption
2025-10-31 01:00:00
Sales margin growth and improved adjusted EBITDA
I am pleased with our third-quarter results. They confirm that we are on the right strategic path towards becoming the leading specialist in the wholesale of pharmaceuticals and health products
2025-08-29 02:00:00
Mölnlycke Health Care: a partnership built on trust, results and shared ambition
Oriola Brand Manager Riikka Alasiurua shares an example of how we build long-term partnerships that deliver value. Not just to our suppliers, but also to pharmacies and their customers
2025-07-21 02:00:00
Strong partnerships drive Distribution growth and profitability
I am pleased with our progress in the second quarter, particularly the continued net sales growth and sales margin improvement, but there is still room for improvement in our profitability
2025-06-13 02:00:00
Medical Information and AE Reporting: The First Line of Pharmacovigilance
The primary role of Medical Information is to ensure that accurate, up-to-date, and unbiased data about medicinal products is readily available. This service is not only essential for patient safety and professional guidance but is also a regulatory requirement
2025-05-30 02:00:00
Helping brands grow; TePe strengthens pharmacy presence in Finland
TePe, a well-known Swedish oral health brand, has been part of Oriola’s portfolio for many years. In 2022, the partnership deepened as Oriola became TePe’s exclusive partner for the pharmacy channel in Finland
2025-04-30 02:00:00
Steady growth and progress towards long-term goals
CEO Katarina Gabrielson comments on Oriola’s Q1 2025 results
2025-03-18 01:00:00
Growth to strategy implementation
For Oriola, 2024 was a good year, marked by sales growth and improved profitability. During 2024, we made steady progress towards becoming the leading specialist in wholesale of pharmaceuticals and health products
2025-03-14 01:00:00
Oriola Patient Support Program - patient engagement in practice
At Oriola, we provide Patient Support Programs (PSPs) designed to promote patient independence. With 15 years of experience, we are the most seasoned vendor in the Nordics
2025-03-05 01:00:00
Strategy implementation enhances financial performance
For Oriola, 2024 was a good year and I am pleased with our accomplishments and financial development, marked by sales growth and improved profitability
2024-10-31 01:00:00
Q3 2024: Improved profitability
CEO Katarina Gabrielson comments on Oriola’s Q3 2024 results: Our solid performance since the start of this year continued in the third quarter, with increased net sales and profitability compared with the previous year
2024-10-09 02:00:00
Tempted by free machine translations? A fluent translation may be full of content errors
While machine translation can be a useful tool, translating medical texts with machine translation alone may put patient safety at risk, writes Elsa Lehtonen from Oriola’s translation team in her blog post
2024-09-30 02:00:00
Terminology work brings speed, cost savings and consistent quality to translations
In medical and pharmaceutical translations, it is crucial that the content of the text is conveyed accurately in the translation to ensure that the message of the text is understood correctly and patient safety is not compromised. Using the right terms makes the text easier to read, ensures that the message is transmitted correctly, and prevents misunderstandings
2024-07-22 02:00:00
Q2 2024: Continued sales growth in both segments
CEO Katarina Gabrielson comments on Oriola’s Q2 2024 results: In the second quarter net sales grew from the previous year despite a softer market environment for pharmaceuticals
2024-06-12 02:00:00
Health technology assessment of pharmacotherapies is about to take a step towards a shared European process – but the impacts are still uncertain
High-quality health economic evaluations play an essential role in the successful pricing and reimbursement process of medicinal products. There are national differences in treatment practices, costs and regulatory requirements, so the same evaluation cannot be applied as-is in different countries for example in the Nordics. In the near future, the health technology assessment evaluation process f...
2024-04-26 02:00:00
Q1 2024: Sales growth and improved profitability
CEO Katarina Gabrielson comments on Oriola’s Q1 2024 results: We had a good start of the year with net sales growing and profitability improving from the previous year
2024-03-05 01:00:00
Sustainability is a key enabler for our business strategy
Looking back at 2023, we can be proud of the strategically significant milestones that we have achieved. We announced our refined strategy, new long-term financial targets and sustainability agenda. These are elements that form a solid foundation as we continue on our path to build the future Oriola
2024-02-29 01:00:00
Will 2024 be the year of adopting AI in the pharmaceutical sector?
As the pharmaceutical sector is data intensive, AI powered tools have significant potential to streamline the data gathering process and support decision-making. This, however, also puts special emphasis on cybersecurity, regulatory environment and workforce development, notes Mikael Nurmi, Oriola’s Chief Digital Officer
2024-02-19 01:00:00
Strong growth in profitability excluding Swedish dose dispensing business
CEO Katarina Gabrielson comments on Oriola’s full-year 2023 results: We made strong progress in the distribution business throughout the year. In 2023, Oriola’s net sales on a constant currency basis grew by 2% and were EUR 1.6 billion
2023-11-01 01:00:00
Solid sales growth in Distribution business, strong financial position
CEO Katarina Gabrielson comments on Oriola’s third quarter in 2023: The stable sales development continued in the third quarter. Oriola’s net sales on a constant currency basis were EUR 376.5 million, which is at last year’s level
2023-10-04 02:00:00
How can a distributor address medicine shortages?
Medicine shortages are a growing challenge worldwide. Proactive preventive measures require close collaboration from all actors in global supply chains. As a pharmaceutical distributor, Oriola can support pharmaceutical companies with data-based supply and demand planning, notes Nicklas Widding, Oriola’s Commercial Director, Sweden
2023-09-07 02:00:00
Dose dispensing improves medication safety in ageing societies
The significance of dose dispensing in improving medication safety increases as the elderly population grows. The service makes it easier for patients to take their medicines in the right way, and decreases unnecessary, overlapping or even incompatible medicines, says Varpu Vilkko, Director of Oriola’s dose-dispensing business in Finland
2023-07-24 02:00:00
Solid performance in Distribution business, profitability burdened by Dose Sweden
CEO Katarina Gabrielson comments on Oriola’s second quarter in 2023: A stable second quarter with net sales growing by 3% to EUR 407 million in constant currency
2023-06-19 02:00:00
GDP in our DNA – what the European guideline for pharmaceutical distribution stands for
In the Nordic countries, pharmacy customers can be sure that they are purchasing quality products without fear of getting counterfeit, contaminated or wrongly stored pharmaceuticals. This is a result of a unique regulatory environment that aims to guarantee safe and reliable supply of medicines and ultimately patient safety, notes Aino Kylmänen, Oriola’s Quality Director
2023-04-28 02:00:00
Solid first quarter – stable net sales in constant currency, profitability in line with our expectations
CEO Katarina Gabrielson comments on Oriola's first quarter in 2023: "I am pleased with the solid start to this year despite some uncertainties in our operating environment."
2023-03-23 01:00:00
One product, one set of rules?
Ensuring compliance in marketing materials related to medical products may sometimes be tricky in different markets. The product might even be classified as an over-the-counter medicine in one country and as a food supplement in another. There are no one-size-fits-all solutions in pharmaceutical materials, and expertise in local requirements is essential, says Minna Kairisalo-Stenfors, leader of O...
2023-02-28 01:00:00
We embarked on a transformation journey at the end of an eventful year of 2022
Katarina Gabrielson in our recently published Annual Review: “It truly was an eventful first year as the CEO of Oriola, and I am very pleased with the successful implementation of our strategic turnaround initiatives, the start of our transformation journey and the steps we took to reconnect with our roots.”
2022-12-08 01:00:00
The patient’s experience is used too little in monitoring pharmacotherapy realisation
Increasing adherence to pharmacotherapy is one of the most significant ways to increase the cost-effectiveness of treatment. Therefore, the patient’s experience should not be ignored in studies investigating the effectiveness of pharmacotherapy, stresses Timo Purmonen in his blog
2022-11-08 01:00:00
How to secure a distribution chain that can handle 2.5 million doses of influenza vaccine during just a few months?
To fulfil this challenging logistics task requires a seamlessly working cold distribution chain and a team of dedicated professionals, writes Fredrik Lillskog, Head of Production, in his blog post
2022-08-18 02:00:00
Develop together, test, ask for feedback, repeat – successful customer experience in digital services springs from interaction
Modern system development incorporates continuous dialogue with the end user, stresses Sampsa Somerma, who steers the development of Oriola’s digital B2B services in Finland
2022-05-23 02:00:00
Introducing new medicines to the market requires in-depth knowledge of the regulatory framework – for the benefit of the patient
Meeting the regulatory obligations to acquire and maintain marketing authorisations for medicinal products requires deep expertise. This is what makes working with regulatory affairs so fascinating, writes Head of Regulatory Affairs and Translations Laura Riihimäki-Lampén in her blog
2022-03-22 01:00:00
Companies’ responsibility under a new spotlight – increased emphasis on sustainable business choices and the energy revolution
More than ever, companies are now expected to stand for their values. In addition to societally responsible actions, the crisis in Ukraine increases the need for energy transition in Europe and using fossil-free energy, writes Tuula Lehto, Vice President, Communications and Sustainability
2022-01-25 01:00:00
”Previously dispatch notes were used to follow medicine’s path – now we have real-time data”
Digitalisation has transformed pharmaceutical distribution over recent decades. This has greatly improved the transparency and quality monitoring of pharmaceutical transport, writes Oriola’s Transport Manager Juhani Jäppinen in his blog